Mentoring a Nigerian junior investigator with a mixed-methods analysis of barriers to colorectal cancer presentation in Nigeria

总结/摘要 本申请是为了响应被标识为NOT-CA的特别利益通知（NOSI）而提交的- 22-036.这是对我们的母公司奖励R 01 CA 246620（PI：Alatise/Du/Kingham）的行政补充 专注于确定尼日利亚结直肠癌（CRC）的风险因素。我们的工作是由快速的 撒哈拉以南非洲CRC发病率和死亡率不断上升。这种日益加重的负担反映在尼日利亚， 非洲人口最多的国家，超过50%的患者在诊断后一年内死亡。这些统计数据 强调需要针对这一有限资源量身定制新的预防、筛查和治疗干预措施 地区然而，作为CRC干预措施基础的传统风险因素远不常见， 尼日利亚与西方人口相比。为了更好地了解CRC的独特风险因素，我们正在招募 600例CRC病例和1，200例匹配的无癌症人群对照，用于病例对照研究，作为 我们的父节点R 01参与者完成一份问卷，以评估人口统计学，人体测量学， 生殖、生活方式、饮食和病史。我们希望获得CRC风险因素的知识，以确定 高风险亚组，可作为筛查和/或早期检测的目标。通过这项工作，我们 建立了研究能力，以促进互补的《儿童权利公约》研究。因此，这方面的总体目标 补助金是通过指导一名有前途初级研究员来加强进行高质量研究的能力 外科医生科学家，并产生证据，将补充我们的R 01的发现。详见本 补充项目，我们将进行混合方法研究，以确定CRC的知识和障碍， 尼日利亚拉各斯患者的CRC早期诊断。≥50岁的健康对照患者（n=350） 在我们的R 01资助的病例对照研究中，将参与定量评估CRC症状的知识 和治疗。在定性阶段，以社区为基础的重点小组在没有CRC的人和深入 将与CRC患者进行一对一访谈。该研究的主要成果是了解 CRC症状，CRC诊断实践和CRC早期诊断的障碍。我们希望这个补充 项目产生丰富的数据，与我们的R 01研究结果配对，可以指导未来CRC诊断的改进 在尼日利亚最终改善治疗方案和结果。

SUMMARY/ABSTRACT This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 22-036. This is an administrative supplement to our parent award R01 CA246620 (PI: Alatise/Du/Kingham) focused on identifying risk factors for colorectal cancer (CRC) in Nigeria. Our work is motivated by the rapidly rising incidence and mortality of CRC in sub-Saharan Africa. This increasing burden is mirrored in Nigeria, the most populous country in Africa, where >50% of patients die within one year of diagnosis. These statistics highlight the need for new prevention, screening, and treatment interventions tailored to this limited-resource region. However, traditional risk factors that serve as a basis for CRC interventions are far less common in Nigeria compared to Western populations. To better understand the unique risk factors of CRC, we are recruiting 600 CRC cases and 1,200 matched cancer-free population-based controls for a case-control study as part of our ongoing parent R01. Participants complete a questionnaire to assess demographic, anthropometric, reproductive, lifestyle, dietary, and medical history. We expect to obtain knowledge of CRC risk factors to identify high-risk subgroups that can be targeted for screening and/or early detection. In addition, through this work, we have built research capacity to facilitate complementary CRC studies. As such, the overarching goals for this supplement are to strengthen capacity for high-quality research through mentorship of a promising junior surgeon-scientist, and to generate evidence that will complement our R01 findings. Specifically in this supplemental project, we will conduct a mixed-methods study to determine knowledge of CRC and barriers to CRC early diagnosis in patients in Lagos, Nigeria. Patients ≥50 years of age (n=350) who are healthy controls in our R01-funded case-control study will participate in quantitative assessment of knowledge of CRC symptoms and treatments. For the qualitative phase, community-based focus groups in people without CRC and in-depth one-on-one interviews with patients with CRC will be conducted. The study's key outcomes are knowledge of CRC symptoms, CRC diagnosis practices, and barriers to CRC early diagnosis. We expect this supplemental project to generate rich data that paired with our R01 findings can guide future improvements in CRC diagnosis in Nigeria to ultimately improve treatment options and outcomes.